Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...

Secondary Myelofibrosis Therapeutics MarketThe global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, ...

Karyopharm (KPTI) announced that, following feedback from the FDA, the company will be replacing Total Symptom Score Improvement of greater ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that, following feedback from the U.S. Food and Drug ...